Predictive Value of Routine Laboratory Parameters in Hospitalized COVID-19 Patients on Severity of Illness

Öz

Aim: Early prediction of Coronavirus disease 2019 (COVID-19) disease severity is important to reduce mortality. Therefore, we sought to determine the clinical correlation between these baseline routine laboratory parameters and their effects on mortality, by retrospectively investigating the routine laboratory parameters of hospitalized COVID-19 patients on admission day. Materials and methods: This retrospective-observational study population consisted of 415 hospitalized COVID-19 patients. Patients were divided into three groups (mild, moderate, and severe) according to their clinical status on admission day. On admission, fifteen routine biochemical and hematological laboratory parameters of COVID-19 patients were evaluated. Results: Aspartate aminotransferase (AST), alanine transaminase (ALT), lactate dehydrogenase (LDH), ferritin, International Normalized Ratio (INR), and d-dimer levels were higher in non-survivors than in survivors, regardless of the initial disease severity group classification. No statistically significant difference was found between the groups in terms of uric acid, monocyte, and platelet count.s Conclusions: There is a need for an urgent scale for detecting COVID-19 severity. AST, ALT, LDH, ferritin, INR, and d-dimer levels may help predict the disease’s severity in COVID-19.

Anahtar Kelimeler

• COVID-19
• biochemical parameters
• disease’s severity

Hastanede Yatan COVID-19 Hastalarında Rutin Laboratuvar Parametrelerinin Hastalığın Şiddeti Üzerindeki Öngörü Değeri

Öz

Amaç: Koronavirus hastalığı 2019 (COVID-19) hastalık şiddetinin erken tahmini, mortaliteyi azaltmak için önemlidir. Bu nedenle, hastaneye yatırılan COVID-19 hastalarının rutin laboratuvar parametrelerini kabul gününde geriye dönük olarak araştırarak, bu temel rutin laboratuvar parametreleri ile mortalite üzerindeki etkileri arasındaki klinik ilişkiyi belirlemeye çalıştık. Gereç ve yöntem: Bu retrospektif-gözlemsel çalışma popülasyonu, hastaneye yatırılan 415 COVID-19 hastasından oluşmaktadır. Hastalar başvuru günlerindeki klinik durumlarına göre (hafif, orta ve şiddetli) üç gruba ayrıldı. Başvuru sırasında COVID-19 hastalarının on beş rutin biyokimyasal ve hematolojik laboratuvar parametresi değerlendirildi. Bulgular: Aspartat aminotransferaz (AST), alanin transaminaz (ALT), laktat dehidrojenaz (LDH), ferritin, Uluslararası Normalleştirilmiş Oran (INR) ve d-dimer seviyeleri, başlangıçtaki hastalık şiddeti grup sınıflandırmasına bakılmaksızın, hayatta kalanlarda hayatta kalanlardan daha yüksekti. Ürik asit, monosit ve trombosit sayıları açısından gruplar arasında istatistiksel olarak anlamlı fark bulunmadı. Sonuç: COVID-19 şiddetini tespit etmek için acil bir ölçeğe ihtiyaç vardır. AST, ALT, LDH, ferritin, INR ve d-dimer seviyeleri, hastalığın COVID-19'daki şiddetini tahmin etmeye yardımcı olabilir.

Anahtar Kelimeler

• COVID-19
• biyokimyasal parametreler
• hastalık şiddeti

Kaynakça

1. 1. https://www.cdc.gov/coronavirus/2019-ncov/index.html [Accessed date: 01. Jan. 2022].
2. 2. Turkish Republic Ministry of Health Covid-19 Guideline (https://covid19bilgi.saglik.gov.tr/depo/rehberler/COVID-19_Rehberi.pdf) [Dated 14.04.2020].
3. 3. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical, and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58(7):1021-8.
4. 4. Yuan J, Zou R, Zeng L, Kou S, Lan J, Li X, et al. The Correlation Between Viral Clearance and Biochemical Outcomes of 94 COVID-19 Infected Discharged Patients. Inflamm Res 2020; 69:599-606.
5. 5. Wang D, Li R, Wang J, Jiang Q, Gao C, Yang J, Ge L, Hu Q. Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study. BMC Infect Dis 2020;20(1):519.
6. 6. Chang HL, Chen KT, Lai SK, Kuo HW, Su IJ, Lin RS, Sung FC. Hematological and biochemical factors predicting SARS fatality in Taiwan. J Formos Med Assoc 2006 Jun;105(6):439-50.
7. 7. Henry BM, de Oliveira MHS, Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med 2020;58(7):1021-8.
8. 8. Thompson S, Bohn MK, Mancini N, Loh TP, Wang C‐ B, Grimmler M, et al. IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID‐19 Patients. Clin Chem Lab Med 2020;58(12):2009–16.

9. 9. Organization, W. H.O (2020). Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance 2 Probable case. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical- [ Accessed date: 01.Jan. 2022].
10. 10. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. Crit Rev Clin Lab Sci. 2020;57(6):389-99.
11. 11. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci 2020;63(3):364-74.
12. 12. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis 2020; 95:304-7.
13. 13. Taneri PE, Gómez-Ochoa SA, Llanaj E, Raguindin PF, Rojas LZ, Roa-Díaz ZM, et al. Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis. Eur J Epidemiol 2020;35(8):763-73.
14. 14. Wendel Garcia PD, Fumeaux T, Guerci P, Heuberger DM, Montomoli J, Roche-Campo F, et al. RISC-19-ICU Investigators. Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort. E Clinical Medicine 2020; 25:100449.
15. 15. Arslan B, Sepici Dinçel A. Biyokimya laboratuvarında COVID-19: Klinik araştırmadan rutine enflamatuvar belirteçler. Yücel D, editör. COVID-19 Pandemisinde Tıbbi Biyokimyanın Artan Rolü. 1. Baskı. Ankara: Türkiye Klinikleri; 2021. s.13-8. [In Turkish].
16. 16. Sun Y, Dong Y, Wang L, Xie H, Li B, Chang C, Wang FS. Characteristics and prognostic factors of disease severity in patients with COVID-19: The Beijing experience. J Autoimmun. 2020; 112:102473. doi: 10.1016/j.jaut.2020.102473.
17. 17. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutiérrez-Ocampo E, Villamizar-Peña R, Holguin-Rivera Y, Escalera-Antezana JP, et al. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020; 34:101623. doi: 10.1016/j.tmaid.2020.101623.
18. 18. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62.
19. 19. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020 ;18(6):1324-9.
20. 20. Li Y, Zhao K, Wei H, Chen W, Wang W, Jia L, et al. Dynamic relationship between D-dimer and COVID-19 severity. Br J Haematol. 2020; 190 (1):e24–e27.
21. 21. Yu HH, Qin C, Chen M, Wang W, Tian DS. D-dimer level is associated with the severity of COVID-19. Thromb Res. 2020;195:219–25.
22. 22. Li C, Hu B, Zhang Z, Qin W, Zhu Z, Zhai Z, Davidson BL, Wang C. D-dimer Triage for COVID-19. Acad Emerg Med.2020; 27 (7):612-3.